Verona Pharma begins dosing RPL554 in Phase IIb COPD trial
admin 26th July 2017 Uncategorised 0Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease (COPD).
More: Verona Pharma begins dosing RPL554 in Phase IIb COPD trial
Source: News